Characteristic | N | % |
---|---|---|
Sex | ||
 Female/Male | 35/30 | 54/46 |
Age (years) | ||
 Median (range) | 53 (24–79) | |
Performance score | ||
 ECOG 0–1 | 65 | 100 |
T stage | ||
 pT1 | 15 | 23 |
 pT2 | 24 | 37 |
 pT3 | 20 | 31 |
 pT4a | 6 | 9 |
Tumor size (cm) | ||
 Median (range) | 2.9 (0.5–8.0) | |
N stage | ||
 pN0 | 6 | 9 |
 pN1 | 3 | 5 |
 pN2b | 15 | 23 |
 cN0/pNxa | 41 | 63 |
Disease stage | ||
 I | 13 | 20 |
 II | 22 | 34 |
 III | 11 | 17 |
 IVa | 19 | 29 |
Staging modality | ||
 CT | 49 | 75 |
 MRI | 6 | 9 |
 18F-FDG-PET | 23 | 35 |
Surgical margin | ||
 < 1 mm/≥1 mm | 46/19 | 71/29 |
Histology | ||
 Adenoid cystic carcinoma | 29 | 45 |
 Carcinoma ex pleomorphic adenoma | 11 | 17 |
 Mucoepidermoid carcinoma | 8 | 12 |
 Lymphoepithelial carcinoma | 6 | 9 |
 Squamous cell carcinoma | 4 | 6 |
 Salivary duct carcinoma | 4 | 6 |
 Adenocarcinoma | 2 | 3 |
 Myoepithelial carcinoma | 1 | 2 |
Histology grading | ||
 Low to intermediate/High | 6/59 | 9/91 |
Pathological features | ||
 Perineural invasion | 35 | 54 |
 Extranodal extension | 12 | 19 |
 Bone invasion | 2 | 3 |
 Skin invasion | 1 | 2 |
 Lymphovascular invasion | 18 | 28 |
Neck dissection | ||
 None | 41 | 63 |
 Ipsilateral elective | 9 | 14 |
 Ipsilateral therapeutic | 15 | 23 |
 Contralateral | 0 | 0 |
 < 18 nodes | 22 | 34 |
 ≥18 nodes | 17 | 26 |
Nodal irradiation | ||
 Extended ENI | 18 | 28 |
 Limited ENI | 47 | 72 |
Concurrent chemotherapy | 24 | 37 |
 Radiotherapy technique | ||
  3D-CRT | 19 | 29 |
  IMRT | 31 | 48 |
  VMAT | 15 | 23 |
Radiotherapy dose (Gy) | ||
 Median (range) | 66 (32–72) |